IN2014DN05665A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN05665A IN2014DN05665A IN5665DEN2014A IN2014DN05665A IN 2014DN05665 A IN2014DN05665 A IN 2014DN05665A IN 5665DEN2014 A IN5665DEN2014 A IN 5665DEN2014A IN 2014DN05665 A IN2014DN05665 A IN 2014DN05665A
- Authority
- IN
- India
- Prior art keywords
- nucleic acid
- acid molecule
- nucleotides
- central stretch
- deoxyribonucleotides
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108091028664 Ribonucleotide Proteins 0.000 abstract 1
- 239000005547 deoxyribonucleotide Substances 0.000 abstract 1
- 239000002336 ribonucleotide Substances 0.000 abstract 1
- 125000002652 ribonucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12000106 | 2012-01-10 | ||
| PCT/EP2012/000089 WO2012095303A1 (en) | 2011-01-10 | 2012-01-10 | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
| EP12006960 | 2012-10-08 | ||
| PCT/EP2013/000056 WO2013104540A1 (en) | 2012-01-10 | 2013-01-10 | New c5a binding nucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN05665A true IN2014DN05665A (enrdf_load_html_response) | 2015-05-15 |
Family
ID=48781063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN5665DEN2014 IN2014DN05665A (enrdf_load_html_response) | 2012-01-10 | 2013-01-10 |
Country Status (18)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3063317B1 (en) | 2013-10-28 | 2020-06-03 | DOTS Technology Corp. | Allergen detection |
| US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| JP7140848B2 (ja) | 2018-05-17 | 2022-09-21 | ザ プロクター アンド ギャンブル カンパニー | 毛髪被覆率分析のためのシステム及び方法 |
| US11172873B2 (en) | 2018-05-17 | 2021-11-16 | The Procter & Gamble Company | Systems and methods for hair analysis |
| EP3586865A1 (en) * | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| US11384357B2 (en) | 2018-06-29 | 2022-07-12 | The Procter And Gamble Company | Aptamers for personal care applications |
| WO2020098968A1 (en) * | 2018-11-12 | 2020-05-22 | Aptarion Biotech Ag | Cxcl8 binding nucleic acids |
| WO2020214784A1 (en) | 2019-04-16 | 2020-10-22 | The Procter & Gamble Company | Aptamers for odor control applications |
| US12039732B2 (en) | 2021-04-14 | 2024-07-16 | The Procter & Gamble Company | Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications |
| CN113150106B (zh) * | 2021-04-26 | 2022-08-16 | 华中农业大学 | 来源于补体成分C5a的抗菌肽及其应用 |
| WO2025196240A1 (en) | 2024-03-20 | 2025-09-25 | Aptarion Biotech Ag | Method of treating a disorder with a c5a inhibitor |
| EP4620474A1 (en) | 2024-03-20 | 2025-09-24 | APTARION biotech AG | Method of treating a disorder with a c5a inhibitor |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140490A (en) | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| EP1438321B1 (de) | 2001-10-26 | 2010-05-26 | Noxxon Pharma AG | Modifizierte l-nukleinsäure |
| EP1585817B1 (en) | 2002-02-20 | 2009-09-02 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
| CA2520550A1 (en) | 2003-04-13 | 2004-10-28 | Enzon Pharmaceuticals, Inc. | Polymeric oligonucleotide prodrugs |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| BRPI0507540A (pt) | 2004-02-09 | 2007-07-03 | Supramol Parenteral Colloids | processo para a produção de conjugados de polissacarìdeos e polinucleotìdeos |
| DK3385384T3 (da) | 2004-02-12 | 2020-06-29 | Archemix Llc | Aptamer-lægemidler nyttige ved behandlingen af komplement-relaterede lidelser |
| US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| JP4950022B2 (ja) | 2004-03-23 | 2012-06-13 | コンプレックス バイオシステムズ ゲーエムベーハー | 自壊性リンカーを有する高分子プロドラッグ |
| WO2006052790A2 (en) | 2004-11-05 | 2006-05-18 | The Children's Hospital Of Philadelphia | Biodegradable linkers for molecular therapies |
| EP1838725A1 (en) * | 2005-01-17 | 2007-10-03 | Jerini AG | C5a receptor antagonists |
| EP4159220A1 (en) | 2006-03-08 | 2023-04-05 | Archemix LLC | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
| KR20090055623A (ko) | 2006-09-15 | 2009-06-02 | 엔존 파마슈티컬즈, 인코포레이티드 | 올리고뉴클레오티드 전달을 위한 방해된 에스테르 기재 생분해성 링커 |
| WO2008052774A2 (en) | 2006-10-31 | 2008-05-08 | Noxxon Pharma Ag | Methods for detection of a single- or double-stranded nucleic acid molecule |
| EP2562256A3 (en) | 2007-09-24 | 2013-06-19 | Noxxon Pharma AG | C5a binding nucleic acids |
| WO2010103868A1 (ja) | 2009-03-11 | 2010-09-16 | オリンパスメディカルシステムズ株式会社 | 画像処理システム、その外部装置およびその画像処理方法 |
| WO2010108657A2 (en) | 2009-03-23 | 2010-09-30 | Noxxon Pharma Ag | C5a binding nucleic acids and the use thereof |
| CN102906265B (zh) | 2010-04-21 | 2016-08-24 | 诺松制药股份公司 | 脂质结合核酸 |
| EP2663640B1 (en) * | 2011-01-10 | 2020-11-04 | APTARION biotech AG | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
| KR20140083039A (ko) | 2011-10-21 | 2014-07-03 | 녹손 파르마 아게 | 글루카곤 결합형 핵산 |
| AU2013209130A1 (en) | 2012-01-10 | 2014-07-10 | Noxxon Pharma Ag | Nucleic acids specifically binding CGRP |
-
2013
- 2013-01-10 MX MX2014008454A patent/MX362061B/es active IP Right Grant
- 2013-01-10 RU RU2014132708A patent/RU2645261C2/ru active
- 2013-01-10 ES ES13700617T patent/ES2786007T3/es active Active
- 2013-01-10 PL PL13700617T patent/PL2802660T3/pl unknown
- 2013-01-10 PT PT137006177T patent/PT2802660T/pt unknown
- 2013-01-10 EP EP13700617.7A patent/EP2802660B1/en active Active
- 2013-01-10 IN IN5665DEN2014 patent/IN2014DN05665A/en unknown
- 2013-01-10 SG SG11201403771SA patent/SG11201403771SA/en unknown
- 2013-01-10 JP JP2014551570A patent/JP6415327B2/ja active Active
- 2013-01-10 WO PCT/EP2013/000056 patent/WO2013104540A1/en active Application Filing
- 2013-01-10 KR KR1020147022321A patent/KR102034203B1/ko active Active
- 2013-01-10 US US14/371,006 patent/US9518265B2/en active Active
- 2013-01-10 SG SG10201605594UA patent/SG10201605594UA/en unknown
- 2013-01-10 DK DK13700617.7T patent/DK2802660T3/da active
- 2013-01-10 CN CN201380009020.9A patent/CN104145018B/zh active Active
- 2013-01-10 BR BR112014016877-6A patent/BR112014016877B1/pt active IP Right Grant
- 2013-01-10 CA CA2860806A patent/CA2860806C/en active Active
- 2013-01-10 AU AU2013209131A patent/AU2013209131A1/en not_active Abandoned
-
2014
- 2014-07-03 IL IL233516A patent/IL233516B/en active IP Right Grant
-
2016
- 2016-12-12 US US15/376,338 patent/US10590424B2/en active Active
-
2018
- 2018-11-30 AU AU2018271388A patent/AU2018271388B2/en active Active
-
2020
- 2020-03-15 US US16/819,102 patent/US11492625B2/en active Active
-
2022
- 2022-11-07 US US17/982,469 patent/US12188021B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN05665A (enrdf_load_html_response) | ||
| WO2014028429A3 (en) | Enzymes and polymerases for the synthesis of rna | |
| WO2014096992A8 (en) | Acetyl transferases and their use for producing carotenoids | |
| UA118014C2 (uk) | Спосіб модифікації днк-мішені | |
| IL250539A0 (en) | Nucleotides modified for nucleic acid synthesis, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes | |
| PH12015501423A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| IN2012DN00403A (enrdf_load_html_response) | ||
| HK1203513A1 (en) | Methods of preparing substituted nucleotide analogs | |
| PH12013500629A1 (en) | Substituted nucleotide analogs | |
| HK1216535A1 (zh) | 取代的核苷、核苷酸及其類似物 | |
| MX2010003109A (es) | Acidos nucleicos de enlace c5a. | |
| IN2014CN02574A (enrdf_load_html_response) | ||
| WO2011079902A3 (en) | Biological inhibitors of ror1 capable of inducing cell death | |
| RS54649B1 (en) | NUCLEIC ACID ANTISENS | |
| WO2011106770A3 (en) | Modified proteins and methods of making and using same | |
| MX2011003229A (es) | Terapia genica con porfobilinogeno desaminasa. | |
| MX343918B (es) | Construccion de adn inmunomodulador no codificante. | |
| EP2488641A4 (en) | SUPERGESPULED MINICIRCLE DNA FOR GENE THERAPY APPLICATIONS | |
| WO2010107955A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING | |
| UY33668A (es) | ?composiciones de las paredes celulares de ácido ribonucleico bacteriano, y métodos para elaborarlas y usarlas?. | |
| WO2011021177A3 (en) | Compositions and methods for prognosis and treatment of prostate cancer | |
| HK1259060A1 (zh) | 抑制肾素原基因或肾素原受体基因表达的单链核酸分子及其用途 | |
| ATE536360T1 (de) | Neues nukleinsäuretransfersystem | |
| MX377713B (es) | Moleculas de ácido ribonucleico pequeño de interferencia especifico de notch 1. | |
| WO2011054939A3 (en) | Compositions and methods for inhibiting expression of kif10 genes |